Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology

Cardiovasc Res. 2018 Aug 1;114(10):1273-1280. doi: 10.1093/cvr/cvy147.


Disturbed metabolism as a consequence of obesity and diabetes may cause cardiac diseases (recently highlighted in the cardiovascular research spotlight issue on metabolic cardiomyopathies).1 In turn, the metabolism of the heart may also be disturbed in genetic and acquired forms of hypertrophic cardiac disease. Herein, we provide an overview of recent insights on metabolic changes in genetic hypertrophic cardiomyopathy and discuss several therapies, which may be explored to target disturbed metabolism and prevent onset of cardiac hypertrophy.This article is part of the Mini Review Series from the Varenna 2017 meeting of the Working Group of Myocardial Function of the European Society of Cardiology.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cardiomyopathy, Hypertrophic / genetics
  • Cardiomyopathy, Hypertrophic / metabolism*
  • Cardiomyopathy, Hypertrophic / pathology
  • Cardiomyopathy, Hypertrophic / physiopathology
  • Endothelium, Vascular / metabolism*
  • Endothelium, Vascular / physiopathology
  • Energy Metabolism* / genetics
  • Genetic Predisposition to Disease
  • Humans
  • Mitochondria, Heart / genetics
  • Mitochondria, Heart / metabolism
  • Mitochondria, Heart / pathology
  • Mutation
  • Myocardium / metabolism*
  • Myocardium / pathology
  • Phenotype
  • Prognosis
  • Risk Factors
  • Sarcomeres / genetics
  • Sarcomeres / metabolism
  • Sarcomeres / pathology